Long-term clinical outcome after botulinum toxin injection in children with nonrelaxing internal anal sphincter

American Journal of Gastroenterology

Volumn 104, Issue 4, 2009, Pages 976-983

  Chumpitazi, Bruno P ^a,b   Fishman, Steven J ^a   Nurko, Samuel ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADOLESCENT; ADULT; ANORECTAL PRESSURE; ANUS SPHINCTER; ANUS SPHINCTER DISORDER; ARTICLE; CHILD; CHILD HOSPITALIZATION; COLON LAVAGE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FECES INCONTINENCE; FEMALE; FOLLOW UP; HIRSCHSPRUNG DISEASE; HUMAN; ILEOSTOMY; INFANT; INJECTION SITE PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCLE RESECTION; NONRELAXING INTERNAL ANUS SPHINCTER; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; TERTIARY HEALTH CARE; TREATMENT RESPONSE; ANAL CANAL; COMPARATIVE STUDY; DEFECATION; DRUG EFFECTS; INTRAMUSCULAR DRUG ADMINISTRATION; NEWBORN; PATHOPHYSIOLOGY; PHYSIOLOGY; RECTAL DISEASES; SMOOTH MUSCLE; TIME; TREATMENT OUTCOME;

ADOLESCENT; ANAL CANAL; BOTULINUM TOXINS, TYPE A; CHILD; CHILD, PRESCHOOL; DEFECATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLE, SMOOTH; NEUROMUSCULAR AGENTS; RECTAL DISEASES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 65449172050     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.110     Document Type: Article

References (27)

1. Miele E, Tozzi A, Staiano A et al. Persistence of abnormal gastrointestinal motility after operation for Hirschsprung's disease. Am J Gastroenterol 2000;95:1226-30.
2. Hyman PE. Defecation disorders after surgery for Hirschsprung's disease. J Pediatr Gastroenterol Nutr 2005;41 (Suppl 1):S62-3.
3. Langer JC. Persistent obstructive symptoms after surgery for Hirschsprung's disease: development of a diagnostic and therapeutic algorithm. J Pediatr Surg 2004;39:1458-62.
4. Bentley JF. Faecal soiling and anal achalasia. Arch Dis Child 1978;53:185-6.
5. Ciamarra P, Nurko S, Barksdale E et al. Internal anal sphincter achalasia in children: clinical characteristics and treatment with Clostridium botulinum toxin. J Pediatr Gastroenterol Nutr 2003;37:315-9.
6. Neilson IR, Yazbeck S. Ultrashort Hirschsprung's disease: myth or reality. J Pediatr Surg 1990;25:1135-8.
7. Martucciello G, Pini Prato A, Puri P et al. Controversies concerning diagnostic guidelines for anomalies of the enteric nervous system: a report from the fourth International Symposium on Hirschsprung's disease and related neurocristopathies. J Pediatr Surg 2005;40:1527-31.
8. Engum SA, Grosfeld JL. Long-term results of treatment of Hirschsprung's disease. Semin Pediatr Surg 2004;13:273-85.
9. Yanchar NL, Soucy P. Long-term outcome after Hirschsprung's disease: patients' perspectives. J Pediatr Surg 1999;34:1152-60.
10. Zaslavsky C, Loening-Baucke V. Anorectal manometric evaluation of children and adolescents postsurgery for Hirschsprung's disease. J Pediatr Surg 2003;38:191-5.
11. Blair GK, Murphy JJ, Fraser GC. Internal sphincterotomy in postpull-through Hirschsprung's disease. JPediatr Surg 1996;31:843-5.
12. De Caluwe D, Yoneda A, Akl U et al. Internal anal sphincter achalasia: outcome after internal sphincter myectomy. J Pediatr Surg 2001;36:736-8.
13. Heikkinen M, Lindahl H, Rintala RJ. Long-term outcome after internal sphincter myectomy for internal sphincter achalasia. Pediatr Surg Int 2005;21:84-7.
14. Wldhaber BE, aPkarinen M, iRntala RJ et al. Posterior myotomy/myectomy for persistent stooling problems in Hirschsprung's disease. J Pediatr Surg 2004;39:920-6; discussion 920-6.
15. Heikkinen M, Rintala R, Luukkonen P. Long-term anal sphincter performance after surgery for Hirschsprung's disease. J Pediatr Surg 1997;32:1443-6.
16. Brisinda G, Cadeddu F, Brandara F et al. Randomized clinical trial comparing botulinum toxin injections with 0.2 per cent nitroglycerin ointment for chronic anal C ssure. Br J Surg 2007;94:162-7.
17. Brisinda G, Maria G, Bentivoglio AR et al. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal C ssure. N Engl J Med 1999;341:65-9.
18. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 2. Am J Health Syst Pharm 2006;63:225-32.
19. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 1. Am J Health Syst Pharm 2006;63:145-52.
20. Gui D, Rossi S, Runfola M et al. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Ther 2003;18:1-16.
21. Jones OM, Brading AF, Mortensen NJ. Mechanism of action of botulinum toxin on the internal anal sphincter. Br J Surg 2004;91:224-8.
22. Minkes RK, Langer JC. A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung's disease. J Pediatr Surg 2000;35:1733-6.
23. Messineo A, Codrich D, Monai M et al. The treatment of internal anal sphincter achalasia with botulinum toxin. Pediatr Surg Int 2001;17:521-3.
24. Irani K, oRdriguez L, Doody DP et al. Botulinum toxin for the treatment of chronic constipation in children with internal anal sphincter dysfunction. Pediatr Surg Int 2008;24:779-83.
25. Nurko S. Complications after gastrointestinal surgery. A medical perspective. In: Walker WA (ed). Pediatric Gastrointestinal Disease, 4th edn. B.C. Decker: Philadelphia, 2004, p. 2111-38.
26. Pehlivanov N, Pasricha PJ. Achalasia: botox, dilatation or laparoscopic surgery in 2006. Neurogastroenterol Motil 2006;18:799-804.
27. Di Lorenzo C, Solzi GF, Flores AF et al. Colonic motility after surgery for Hirschsprung's disease. Am J Gastroenterol 2000;95:1759-64.